EXPLORE!

FDA Approves Rezdiffra: First Drug for NASH

  436 Views

Emedinexus    17 June 2025

The FDA has granted accelerated approval for Rezdiffra, marking it as the first drug specifically for treating non-alcoholic steatohepatitis (NASH), a serious form of fatty liver disease. This approval allows for earlier access to treatments for conditions with significant unmet medical needs, based on intermediate clinical endpoints that suggest potential clinical benefits.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.